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Abstract
Background: Bipolar disorder is the fourth most common mental health condition, affecting ~ 1% of UK adults. Lithium is
an effective treatment for prevention of relapse and hospital admission, and is widely recommended as a first-line treatment.
We previously showed in other areas that laboratory testing patterns are variable with sub-optimal conformity to guidance.
We therefore examined lithium results and requesting patterns relative to monitoring recommendations.
Methods: Data on serum lithium levels and intervals between requests were extracted from Clinical Biochemistry
laboratory information systems at the University Hospitals of North Midlands, Salford Royal Foundation Trust and
Pennine Acute Hospitals from 2012 to 2018 (46,555 requests; 3371 individuals). Data were examined with respect to
region/source of request, age and sex.
Results: Across all sites, lithium levels on many requests were outside the recommended UK therapeutic range (0.4–0.99
mmol/L); 19.2% below the range and 6.1% above the range (median [Li]: 0.60mmol/L). A small percentage were found at
the extremes (3.2% at < 0.1mmol/L, 1.0% at ≥1.4mmol/L). Most requests were from general practice (56.3%) or mental
health units (34.4%), though those in the toxic range (≥1.4mmol/L) were more likely to be from secondary care (63.9%). For
requesting intervals, there was a distinct peak at 12weeks, consistent with guidance for those stabilised on lithium therapy.
There was no peak at 6months, as recommended for those aged < 65 years on unchanging therapy, though re-test
intervals in this age group were more likely to be longer. There was a peak at 0–7 days, reflecting those requiring closer
monitoring (e.g. treatment initiation, toxicity). However, for those with initial lithium concentrations within the BNF range
(0.4–0.99mmol/L), 69.4% of tests were requested outside expected testing frequencies.
Conclusions: Our data showed: (a) lithium levels are often maintained at the lower end of the recommended therapeutic
range, (b) patterns of lithium results and testing frequency were comparable across three UK sites with differing models of
care and, (c) re-test intervals demonstrate a noticeable peak at the recommended 3-monthly, but not at 6-monthly intervals.
Many tests were repeated outside expected frequencies, indicating the need for measures to minimise inappropriate testing.
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Background
Bipolar disorder is the 4th most common mental health
condition, affecting approximately 1% of adults [1]. Indi-
viduals with bipolar disorder typically have recurrent epi-
sodes of elevated mood (mania) and periods of depressed
mood, which may last for several weeks. A combination of
therapies is often required to manage different aspects of
bipolar disorder, including pharmacological treatments,
psychological therapies and lifestyle advice.
Lithium is the most effective treatment for prevention
of relapse and hospital admission in people with bipolar
disorder, and is recommended by The National Institute
for Health and Care Excellence (NICE) in the UK as a
first line long-term treatment [2], as well as in clinical
practice guidelines in the USA, Canada, Japan, the
Netherlands, and Australia and New Zealand, and in the
International Society for Bipolar Disorders [3–5]. Lith-
ium is also used to treat other conditions such as recur-
rent depression [6].
However, lithium treatment is associated with both
short-term and long-term risks. Insufficient dose, poor
adherence or sudden discontinuation of lithium can re-
sult in relapse. In contrast, acute lithium toxicity can
presents with a variety of clinical manifestations includ-
ing renal, neurological, gastrointestinal, cardiac and
endocrine abnormalities [7].
Because of these factors, maintaining blood lithium con-
centration within a relatively narrow therapeutic index is
desirable. NICE guidelines currently advise maintaining
serum lithium concentration between 0.6 and 0.8mmol/L,
or between 0.8 and 1.0mmol/L in people who have re-
lapsed whilst taking lithium, or people who have sub-
threshold symptoms with functional impairment [2]. The
British National Formulary (BNF) recommends that
serum lithium is maintained within the range 0.4–1.0
mmol/L, focusing on the lower end of this range for those
on maintenance therapy and in elderly patients [6].
Recommended monitoring intervals for lithium vary
according to individual status. For people initiating lith-
ium therapy, NICE guidelines recommend weekly moni-
toring until a stable baseline is established [2].
Subsequently, it is suggested that serum lithium be mon-
itored on a three-monthly basis for the first year of treat-
ment, increasing to six-monthly for people under 65
years of age with no changes affecting lithium concen-
tration. More frequent monitoring may be initiated for a
variety of reasons, including dose and formulation
changes, changing other medications or intercurrent ill-
ness. In particular, individuals with potentially toxic
serum lithium concentrations (> 1.4 mmol/L) should
have serial daily lithium measurements taken to ensure
elimination and avoid rebound toxicity [8].
We have shown in other areas that laboratory testing
patterns are highly variable and that conformity to
guidance in sub-optimal [9–11]. This study therefore
aims to assess lithium results and patterns of requesting,
and compare these findings to current guidance on lith-
ium requesting. We examined these using clinical la-
boratory data collected from three large UK centres,
where the approach to managing patients with bipolar
disorder and ordering lithium testing varies.
Methods
Data collection
All lithium requests received by the Clinical Biochemis-
try Departments at the University Hospitals of North
Midlands (UHNM), Salford Royal Foundation Trust
(SRFT) and Pennine Acute Hospitals NHS Trust (PAT)
between 2012 and 2018 were extracted from the respect-
ive Laboratory Information and Management Systems
(49,584 requests). These sites represented mixed rural
and urban populations. Each used different approaches
to monitoring lithium therapy in terms of the relative
proportion of tests requested by primary and specialist
care. People with a single lithium request, those initiat-
ing lithium therapy in the final year of data collection
and those under the age of 18 were excluded, leaving a
data set of 46,555 requests from 3371 individuals.
Data categorisation
Sources of request were categorised as General Practices
(GPs), Mental Health Units (MHUs; including inpatient
and outpatient requests), Acute Care (including Emer-
gency Departments, acute medical & surgical units, etc.),
Secondary Care (all acute hospital inpatient and out-
patient, excluding Acute Care sources) and Other (in-
cluding unknown sources). The demographics of this
data set are shown in Table 1.
Lithium concentrations were grouped into categories:
< 0.10 mmol/L (undetectable by the laboratory assay);
0.10–0.39 mmol/L (below the BNF recommended thera-
peutic range and where lithium therapy is generally inef-
fective) [6, 12]; 0.4–0.59 mmol/L (within the BNF range,
but below the NICE therapeutic range) [2, 6]; 0.60–0.79
mmol/L (within both BNF and NICE ranges); 0.8–0.99
mmol/L (within both BNF and NICE ranges, but where
BNF recommends more frequent monitoring) [6]; 1.0–
1.39 mmol/L (above both BNF and NICE ranges, and
where very few patients gain additional benefit) [2, 6, 12]
and ≥1.4 mmol/L (were toxicity is likely) [13].
Intervals between lithium tests were calculated as
number of days until the next lithium result was re-
quested for each person.
Data analysis
This study represented a service evaluation and audit of
practice against the guidelines outlined by NICE and the
BNF [2, 6]. According to the decision tool provided by
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the UK Health Research Authority [14], this study was
not considered to be research and did not require NHS
Research Ethics Committee review. It therefore did not
require ethical committee approval. All data extracted
from Laboratory Information and Management Systems
were anonymised and local Trust processes were used to
obtain approval for use of the data.
All statistical analyses were performed using Stata
(version 14; College Station, TX). We used the Kruskal-
Wallis test for comparisons of median lithium concen-
trations across sites and Mann-Whitney U test for com-
parisons between males and females. Linear regression
was used to assess the association between lithium con-
centration with age. Chi-squared analyses were used to
compare differences in proportions within categories
(lithium concentration or requesting interval groups) be-
tween sites, source of request, gender and age groups.
Results
Demographics
Table 1 shows a demographic summary of people in-
cluded in the study. At all three trusts, the majority of
requests came from either GP practices or MHUs, with
a minority from acute care units, secondary care, or
other sources. However, the proportion of requests from
GP practices compared to MHUs varied between Trusts.
At PAT, GP requests comprised 73.4% of total requests,
whereas at UHNM, most requests originated from MHU
(59.6%; GP practice requests comprised 32.0%). At
SRFT, GP and MHU requests were evenly split (44.7%
and 46.3%, respectively).
Lithium concentrations
Overall, the median lithium concentrations were at the
lower limit of the therapeutic range (0.60 mmol/L; IQR
0.44–0.76) (Table 2). The median lithium concentrations
were generally lowest in samples from the SRFT and high-
est from UHNM (p< 0.001, Kruskal-Wallis test) and were
slightly higher in females (0.60mmol/L; IQR 0.45–0.76)
than males (0.59mmol/L; IQR 0.43–0.75; p< 0.001, Mann-
Whitney U test). There was also a statistically significant
positive correlation between lithium concentration and age
(p< 0.001, linear regression), though the strength of this as-
sociation was not clinically meaningful (r=0.07).
The proportion of lithium tests in the key categories re-
ferred to in guidance showed that, in the overall dataset,
74.7% of results were within the 0.4–0.99mmol/L range,
with the majority of these in the lower part of this range.
Approximately 30% of lithium results fell into 0.4–0.59
mmol/L range (within the BNF recommended range).
The distribution of lithium concentrations from re-
quests across the three Trusts (Fig. 1) showed that the
lithium concentration profile for each of the Trusts were
broadly similar, with a peak at approximately 0.6 mmol/
L. This indicated that almost half of results (49.3%) were
below the NICE recommended therapeutic window,
while only 6% were above the window. A large peak was
noted at < 0.1 mmol/L; reflecting results below the de-
tectable range of the assay. When examined in terms of
proportions within the lithium concentration categories
between sites (Table 2), while the overall patterns were
broadly similar, they were statistically different (χ212=
332.5, p< 0.001) with a slightly higher proportion of re-
sults from UHNM within the range 0.8–0.99 mmol/L
and lower proportion in the < 0.1 and 0.1–0.39 mmol/L
categories. This was reflected in the higher overall me-
dian lithium concentration for UHNM. A small percent-
age of results were found at the extremes - less than 4%
at < 0.1 mmol/L and less than 2% at > 1.4 mmol/L –
across all three sites.
Similarly, lithium requests falling into each category
were split by source (Table 2). This demonstrated that
Table 1 Study demographics
PAT % SRFT % UHNM % Total %
Number of patients Total 1613 1162 596 3371
Sex Male 670 41.5 469 40.4 238 39.9 1377 40.8
Female 943 58.5 690 59.4 358 60.1 1991 59.1
Age (years) Median (IQR) 50 (39–62) 53 (41–68) 54 (42–67) 52 (40–65)
Number of requests GP 17,118 73.4 5890 44.7 3215 32.0 26,223 56.3
MHU 3938 16.9 6101 46.3 5996 59.6 16,035 34.4
Secondary Care 1658 7.1 642 4.9 559 5.6 2859 6.1
Acute Care 461 2.0 470 3.6 177 1.8 1108 2.4
Other 144 0.6 71 0.5 115 1.1 330 0.7
Total 23,319 50.1 13,174 28.3 10,062 21.6 46,555
Requests per patient 14.5 11.3 16.9 13.8
Abbreviations and definitions: PAT Pennine Acute Trust, SRFT Salford Royal Foundation Trust, UHNM University Hospitals of North Midlands, GP General Practice,
MHU Mental Health Unit (including inpatient and outpatient), Secondary Care: Acute hospital inpatient and outpatient, excluding Acute Care sources; Acute Care:
Acute hospital Emergency Departments and acute medical/surgical units; Other: all other sources of requests, including unknown sources, IQR Inter-quartile range
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the distribution of source of request differed significantly
by lithium concentration (χ224=4002, p< 0.001). For
those cases were tests were within the range 0.4–0.99
mmol/L, most tests were requested by GPs or MHUs,
supporting the view that most routine management of
lithium dosing for those on stable therapy is being per-
formed by these units. For results in the two toxic
ranges (1.0–1.39 and ≥1.4 mmol/L), a greater proportion
were requested from acute and, to a lesser extent,
secondary care when compared with non-toxic levels.
This was reflected in the higher median lithium concen-
tration for requests from acute care sources.
Requesting intervals
Figure 2 shows the relative frequencies of intervals be-
tween pairs of requests for the total group (Fig. 2a) and
for each category of lithium concentration (Fig. 2b-h).
Overall, there was a distinct peak at 12 weeks, as
Table 2 Detailed breakdown of serum lithium concentration profile by site and source of requests




< 0.1 0.1–0.39 0.4–0.59 0.6–0.79 0.8–0.99 1.0–1.39 ≥1.4 Total
Site
PAT 3.5% 16.0% 29.9% 30.2% 14.3% 5.1% 1.1% 100.0% 0.60 (0.44–0.76)
SRFT 3.3% 17.5% 32.6% 29.9% 12.0% 3.9% 0.8% 100.0% 0.58 (0.43–0.73)
UHNM 2.6% 14.0% 27.4% 30.5% 17.9% 6.4% 1.2% 100.0% 0.63 (0.47–0.80)
Total 3.2% 16.0% 30.1% 30.2% 14.4% 5.1% 1.0% 100.0% 0.60 (0.44–0.76)
Source
GP 53.7% 47.7% 57.2% 60.0% 60.6% 53.7% 24.4% 56.4% 0.61 (0.46–0.76)
MHU 31.3% 39.1% 35.6% 33.9% 32.4% 28.3% 11.1% 34.4% 0.58 (0.42–0.74)
Acute care 4.5% 3.0% 1.5% 1.1% 1.8% 6.0% 38.0% 2.4% 0.66 (0.38–1.10)
Secondary care 9.3% 9.2% 5.0% 4.3% 4.7% 11.3% 25.9% 6.1% 0.53 (0.34–0.75)
Other 1.3% 1.0% 0.6% 0.7% 0.5% 0.7% 0.6% 0.7% 0.57 (0.38–0.68)
Total 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
The categories within the NICE- and BNF-recommended therapeutic range are highlighted in bold: 0.4–0.59 mmol/L for BNF extension to the NICE-recommended
range, 0.6–0.79 mmol/L for NICE-recommended range for people receiving routine lithium treatment; 0.8–0.99 mmol/L for NICE-recommended range for people
who have relapsed whilst taking lithium, or people who have sub-threshold symptoms with functional impairment
Fig. 1 Serum lithium concentration profile for each site. The categories within the NICE- and BNF-recommended therapeutic range is indicated
by shading: light grey for BNF extension to the NICE-recommended range (0.4–0.59 mmol/L), mid grey for NICE-recommended range for people
receiving routine lithium treatment (0.6–0.79 mmol/L); dark grey for NICE-recommended range for people who have relapsed whilst taking
lithium, or people who have sub-threshold symptoms with functional impairment (0.8–0.99 mmol/L)
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suggested in NICE and BNF guidance for those stabi-
lised on lithium therapy. There was no peak evident at 6
months as suggested in NICE guidance for those less
than 65 years old on unchanging therapy. As 22,732 re-
quests were from the 15,514 people aged < 65 years of
age whose initial lithium concentration was in the range
0.4–0.99 mmol/L, we would have expected a distinct
peak of test requests at 6 months. Moving these cases
from 3- to 6-monthly testing would reduce the number
of lithium request by up to 6644 per year across the re-
gions serviced by these three laboratories.
There was a peak at 0–7 days, reflecting those requir-
ing closer monitoring (e.g. at treatment initiation or with
results in the toxic range). It was also noted that there
were spikes of tests requested at weekly intervals
throughout, suggesting that there may be a weekly
recurring clinic at which samples were collected. There
were no noticeable differences in overall pattern when
stratified by site (data not shown).
We also examined the pattern of requesting intervals
based on initial lithium result. This showed distinct pat-
terns of request interval for each category of lithium re-
sult (Fig. 2b-h). For results within the NICE and BNF
recommended range categories (0.4–0.59 mmol/L, 0.6–
0.79 mmol/L and 0.8–0.99 mmol/L), the modal interval
was 84 days (12 weeks). In contrast, peaks are noted at
much earlier intervals for other categories: at 7 days for
< 0.1 mmol/L and 0.1–0.39 mmol/L concentrations; and
at 1 day for 1.0–1.39 mmol/L and > 1.4 mmol/L
concentrations.
Tables 3 and 4 shows the proportion of cases within
defined interval categories, split by sex, age (Table 3)
Fig. 2 Frequency of intervals between consecutive lithium requests (truncated at 1 year). Percentages of requests reflect daily requests and are
show for the total number of requests (panel a) and categorised by initial lithium concentration (panels b-h)
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and initial lithium concentration (Table 4). While
broadly similar, the pattern of test requesting intervals
differed statistically by both sex (χ27=106.4, p< 0.001)
and age (χ27=370.4, p< 0.001). Hence, intervals were
more likely to be shorter in females (46.3% less than 11
weeks) compared with males (43.0% less than 11 weeks;
p< 0.001, OR 1.15, 95% CI 1.10–1.19). Those patients
aged over 65 years (66.7% less than 14 weeks) were also
more likely to have shorter intervals compared with
those aged ≤65 years (58.5% less than 14 weeks; p< 0.001,
OR 1.42, 95% CI 1.36–1.48).
Table 4 shows the link between testing interval and
lithium concentration and illustrates the large propor-
tion of tests requested outside recommended retesting
intervals. For example, for those with initial lithium con-
centrations within the range 0.4–0.99 mmol/L where the
recommended intervals (with the exceptions defined in
the Introduction) is generally 12 weeks or 26 weeks, a
large proportion were requested either before this time
(< 11 weeks; 36.7%), in the gap between these two rec-
ommended intervals (weeks 14–22; 22.5%) or later than
recommended > 27 weeks (10.2%). In those cases in the
toxic range > 1mmol/L, there were a number that were
requested later than recommended: 64.6% were re-tested
later than 7 days in those with an initial lithium level of
1.0–1.39mmol/L and 39.5% were retested later than 1 day
in those with initial lithium concentrations of > 1.4mmol/
L. Similarly, those in the < 0.4mmol/L category might be
expected to be re-checked at 1–2 weeks during lithium
dose up-titration, for example. However, 40.3% were re-
tested outside the 2–7 days and 8–76 days categories.
Discussion
The use of lithium as a treatment for bipolar disorder
has been established for over forty years. In the UK,
USA, Canada, Japan, the Netherlands and Australia and
New Zealand, lithium is currently recommended as a
first line treatment for bipolar disorder [1–5]. Lithium
has a low therapeutic index, with a narrow interval be-
tween therapeutic and toxic doses. People taking lithium
therefore need to ensure they receive sufficient dosage
for clinical effect, whilst minimising the risk of side ef-
fects and toxicity. If tolerated, lithium has been shown
to be an effective treatment for bipolar disorder.
Table 3 Intervals between lithium requests stratified by sex, and age
Interval between requests Sex Age (years)
Male Female ≤65 > 65
0–1 days 2.3% 2.6% 2.1% 3.4%
2–7 days 7.9% 9.7% 8.4% 10.3%
8–76 days (weeks 2 to 10) 32.8% 34.1% 32.7% 35.4%
77–98 days (weeks 11 to 13) 16.3% 16.0% 15.4% 17.6%
99–160 days (weeks 14 to 22) 25.1% 24.8% 26.0% 22.5%
161–189 days (weeks 23 to 26) 3.0% 2.7% 3.0% 2.4%
190–365 (weeks 27 to 51) 10.5% 8.5% 10.3% 7.2%
> 365 (weeks 52 and above) 2.1% 1.7% 2.2% 1.1%
Total 100.0% 100.0% 100.0% 100.0%
Table 4 Intervals between lithium requests stratified by initial lithium concentrations
Interval between requests Lithium concentration (mmol/L)a
< 0.1 0.1–0.39 0.4–0.59 0.6–0.79 0.8–0.99 1.0–1.39 > 1.4
0–1 days 2.6% 2.2% 1.0% 1.0% 1.6% 9.8% 60.5%
2–7 days 14.1% 16.2% 6.5% 4.3% 7.4% 25.6% 26.6%
8–76 days (weeks 2 to 10) 45.6% 46.4% 30.4% 27.8% 33.0% 46.0% 9.9%
77–98 days (weeks 11 to 13) 7.6% 13.1% 24.5% 27.0% 23.0% 6.1% 0.2%
99–160 days (weeks 14 to 22) 11.7% 12.6% 22.0% 23.7% 21.1% 7.3% 1.3%
161–189 days (weeks 23 to 26) 3.4% 2.7% 5.2% 5.9% 4.9% 1.5% 0.4%
190–365 (weeks 27 to 51) 8.8% 5.0% 8.5% 8.6% 7.5% 2.9% 0.6%
> 365 (weeks 52 and above) 6.1% 1.7% 2.0% 1.8% 1.5% 0.8% 0.4%
Total 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Categories where the majority of tests would be expected based on guidelines are highlighted in bold
alithium concentration was based on the result of the first lithium of each pair of tests that define an interval
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Improper dosing may lead to non-adherence, prescrip-
tion of additional or alternative medication, or failure of
therapy, leading to relapse.
Lithium levels
In our study, the mean serum lithium concentration was
found to be around 0.6 mmol/L across all three centres.
This is at the lower end of the NICE recommended
range [2], but within that recommended by the BNF [6].
Indeed, the overall pattern of lithium concentrations was
very similar across the three centres suggesting that, des-
pite differences in proportion of tests requested by gen-
eral practices and MHUs, there is consensus on target
levels. Approximately 30% of results were between 0.6
and 0.8 mmol/L and a further 30% between 0.4 and 0.6
mmol/L. The finding that around 45% of results fall into
the range recommended by NICE for the majority of our
patient population (0.6–1.0 mmol/L) is in keeping with
the findings of Nikolova et al. [4] who found that serum
levels were within this range in 50.7% of cases.
Although it may appear concerning that such a large
proportion of lithium test results are outside the NICE
recommended therapeutic range, this may be indicative
of widespread use of the BNF ranges in local guidelines,
or pragmatic prescribing by clinicians or inconsistencies
between individual recommendations, as summarised by
Nederlof et al. [3]. Local Shared Care Agreements cover-
ing the three centres in this manuscript appear to refer
to the BNF quoted range of 0.4–1.0 mmol/L [15–17]. A
lack of relevant, well-designed studies in determining
the optimal concentration has been noted [5]. Several re-
views quoted by Nolen et al. [5] suggest the minimum
effective serum lithium concentrations may be as low as
0.4 mmol/L. In the UK, NICE guidance published in
2018 [2], recommends clinicians consider maintaining
serum lithium level at a relatively conservative range of
0.6–0.80 mmol/L, or 0.8–1.0 mmol/L in people who have
relapsed whilst taking lithium, or people who have sub-
threshold symptoms with functional impairment. More
recently, Nolen et al. [5], as part of the ISBD/IGSLI Task
Force on treatment with lithium, concluded that serum
lithium concentration should be maintained at 0.6–0.8
mmol/L, with the option to reduce to 0.4–0.6 mmol/L in
cases of good response but poor tolerance; or an in-
creased concentration of 0.8–1.0 mmol/L in cases of in-
sufficient response but good tolerance. A controlled
study by Gelenberg et al. [18] found that patients ran-
domly assigned to a “low” lithium level (0.4–0.6 mmol/
L) had fewer side effects but more illness episodes than
patients in the “standard” lithium group (0.8–1.0 mmol/
L). However, the lithium levels of some of the patients
in the low-lithium group decreased relatively rapidly
from their previous treatment levels, a decrease that
could have increased their risk of relapse. It must be
noted that lithium monitoring is an individualised
process, and clinical team must be confident to tailor
dosages as best suits the person taking lithium. A num-
ber of individuals in our cohorts may be achieving thera-
peutic benefit at a lower serum lithium concentration,
and the prescribing clinician may have chosen to main-
tain this, rather than risk additional side effects with an
increased dose. This may therefore be reflected in both
our findings and those of Nikolova et al. [4], who also
identified a large proportion (42.4%) of cases with levels
below the recommended 0.6–1.0 mmol/L.
Those patients with lower blood lithium concentra-
tions (< 0.4 mmol/L) comprised 19.2% of cases overall.
This is higher than that described by Parton et al. [19]
who identified that, in a study of 2776 patients with
affective disorders from 35 UK MHUs, lithium levels
were below 0.4 mmol/L in approximately 10% of pa-
tients. This difference is unlikely to be due to the source
of the requests as out equivalent data for MHUs was
similar to the overall figure at 21.1%. Those with
undetectable levels may reflect lack of adherence to
medication, while those with low but detectable levels
(0.1–0.39 mmol/L) may indicate partial adherence or
other scenarios such as up-titration of lithium following
initiation of treatment or monitoring after a phase of
lithium toxicity. Whilst the majority of these appear to
be managed in GPs or MHUs, a larger proportion of
these tests were requested in acute or secondary care
than those with results within the therapeutic range.
Approximately 5% of results could be defined as over-
treated (range 1–1.39 mmol/L). However, this may re-
flect people who have not yet stabilised their dosage or,
for those requested in acute or secondary care, monitor-
ing those experiencing toxicity-associated symptoms. In
addition, this group of results may include people who
have had samples taken less than 12 h post previous
dose. These proportions are again in keeping with the
findings of Nikolova et al. [4], who identified levels
above 1 mmol/L in 6.9% of cases. Reassuringly, only a
small proportion of results (1%) were within the toxic
range (> 1.4 mmol/L), and a large proportion of these re-
sults were requested by either in acute (38.0%) or sec-
ondary (25.9%) care, suggesting an appropriate response
to potential toxic side-effects.
Requesting intervals
Examining the overall patterns of testing frequency
(Fig. 2a); we noted that there were multiple spikes of
requesting it weekly intervals. This would indicate a
tendency for attendance and phlebotomy at clinics on
the same day each week within GP practices and
MHUs. This has been seen elsewhere where regular
testing is required, both by us [9] and others [20].
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According to clinical guidance, monitoring serum lith-
ium concentration at regular intervals is necessary, de-
pending on individual status. More frequent monitoring
is recommended for those beginning or changing lith-
ium dosage, changing other medications or experiencing
intercurrent illness (1 week intervals); and less frequent
monitoring is recommended for people who are stable
(3–6 months) [2]. Given this advice, it might be expected
that frequency plots would show three major peaks, cor-
responding to populations of unstable therapy (1 week)
and at stable therapy (at 3 and 6months), with a further
peak at 1 day for those with lithium levels in the toxic
range. Our data indicates that this is broadly true. How-
ever, there was a large number of tests performed at
non-recommended intervals that are outwith guidance,
and there was no evidence of any defined peak at 6
months. In some cases, these tests will be appropriate:
for example, people unable to attend their 3-monthly ap-
pointment may attend one shortly before or after; or
those who become unwell.
NICE guidelines recommend maintaining serum lith-
ium concentration between 0.6 and 0.8 mmol/L for most
people taking lithium, with a higher concentration of 0.8
to 1.0 mmol/L for individuals who have had previous re-
lapse [2]. In the absence of other factors affecting lith-
ium, these patients could be expected to adhere to a 3-
monthly monitoring regimen. Although it can be seen
that the peak representing the most common interval
until next test for these results was around 12 weeks,
with a smaller peak at 7 days, it is clear that the majority
of results are not being repeated within an appropriate
time frame; either too early or too late. Further analysis
shows that, for those with these lithium concentrations
of 0.4–0.99 mmol/L, 36.7% of tests were requested be-
fore 11 weeks, 22.5% between 14 and 22 weeks and
10.2% after 27 weeks.
The absence of a significant peak of testing at 6
months likely relates to the logistics of testing; most lith-
ium clinics in the UK are configured to test at 3-month
intervals and local shared care agreements for the cen-
tres covered made no mention of 6-monthly lithium
monitoring [15–17]. A significant number of tests (22,
732) were performed in those aged < 65 years of age
whose lithium concentration was in the range 0.4–0.99
mmol/L, where 6-monthly lithium testing is indicated,
so we would have expected to see a clear peak at this
time point if NICE recommendations were being
followed. This was not evident on the frequency plots,
though we did identify that those aged < 65 years were
more likely to have longer retest intervals. Interestingly,
Collins et al. showed that age < 65 years was linked to re-
duced likelihood of following NICE audit standards for
lithium monitoring [12], suggesting a reason for the lack
of a noticeable peak at 6 months. Following the guidance
regarding 6-monthly testing would save up to 6644 lith-
ium tests per year, which, if extrapolated to a UK popu-
lation would equate to around 200,000 fewer tests per
year (equivalent to approximately £250,000 per year).
Clearly, a number of these patients will have more fre-
quent tests for other reasons, though it does appear that
the 6-monthly guidance is largely not being followed,
leading to excessive inappropriate testing.
Conversely, there some people for whom the interval
between tests was more than 12months, perhaps indicat-
ing challenges with attendance in this patient group [21].
We did identify a significant association between sex
and retesting interval with women demonstrating gener-
ally shorter intervals. This is not expected from guidance
which does not discriminate between males and females
[2, 6], while Collins et al. did not identify any significant
associations with sex [12]. However, our large sample
size is powered to detect differences that are not clinic-
ally meaningful and the observation of an odds ratio of
only 1.15 suggests that this is not clinically important.
Reassuringly, for results outside the NICE and BNF
recommended lithium concentrations, the repeat inter-
vals were generally shorter. The toxic limit for lithium is
usually taken as > 1.4 mmol/L, and for results at this
level and above, the majority (60.5%) were repeated ei-
ther same day or next day and over 87% within 7 days.
However, a significant minority (12.9%) were repeated
more than 1 week later. As discussed previously, results
at this level are usually managed in acute or secondary
care, and likely represent active monitoring of lithium
overdose. Those requests with lithium levels in the range
1.0–1.39mmol/L also showed a shorter re-testing fre-
quency, but with a generally longer interval than those
with toxic levels. However, again, there were a significant
number that were not re-checked within 1 week (n=1462;
64.6% of requests). Overall, these may represent those
with previously toxic levels under closer monitoring, or
those patients who are more disengaged from the service.
Strengths and limitations
Our study utilises data on large numbers of patients
across three UK sites, and highlights the potential of
laboratory-based data to examine longitudinal monitor-
ing in a range of conditions [9–11]. However, this route
of data collection has the disadvantage of not allowing
collection of other clinical data such as diagnosis, time
of treatment initiation, lithium dosage, etc., which may
assist in the interpretation of the data. The three sites
reflected differing models of management of people with
bipolar disorder, with each representing mixed urban
and rural populations. For example, monitoring of
people on lithium therapy served by the UHNM labora-
tory is predominantly managed by MHUs, the majority
of lithium requests for patients served by the PAT
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laboratory were arranged in primary care, while those served
by SRFT were approximately equally distributed between
primary and specialist mental health care. This facilitated as-
sessment of the generalisability of our findings.
Compared with some studies [12, 22], we were not
able to determine from clinical laboratory records spe-
cific information on the reason for each lithium test re-
quest or the underlying primary psychiatric diagnosis. In
addition to its use in the treatment and prophylaxis of
bipolar disorder, lithium is licenced in the treatment of
mania, treatment-refractory recurrent depression and
aggressive or self-harming behaviour [6, 12]. In an excel-
lent review of conformity to lithium monitoring across
38 UK mental health trusts by Collins et al. [12], the au-
thors showed that around 60% of patients on lithium
therapy had a primary diagnosis of bipolar disorder, 25%
had unipolar depression and 11% had a psychotic
spectrum disorder. While we recognise that this is a poten-
tially important limitation, the recommendations for lithium
monitoring within national and international guidance are
consistent regardless of indication [2, 23, 24], and many
Local Shared Care Agreements focus on lithium therapy, ra-
ther than specific primary diagnosis, as a focus for monitor-
ing [15–17]. We do accept that the lack of this information
did not allow us to stratify findings by primary diagnosis, and
this represents an ongoing challenge in the use of the other-
wise extremely valuable laboratory-based datasets.
Our data is also based on the presence of at least one
lithium test and may therefore underestimate those who
are on lithium treatment, but who are not tested. How-
ever, our data does agree with those of other studies in
terms of tests per year. However, in addition, our study
examines each result and its follow-up interval on a
patient-by-patient basis, thereby giving a more detailed
view of intervals between requests. Furthermore, our
data is based on a large number of patients and is con-
sistent across three sites over 6 years with differing
models of distribution of care between general practice
and specialist mental health care.
Conclusions
In summary, our findings indicate that; (a) there is a ten-
dency to manage patients at levels at the lower end of
the NICE-recommended therapeutic range, (b) those
with elevated levels are frequently managed in acute or
secondary care, (c) patterns of lithium results and testing
frequency are comparable across three UK sites with dif-
fering models of care, (d) intervals between tests demon-
strate a noticeable peak at the recommended 3-monthly
interval, but there was no evidence of any noticeable
peak of testing at 6-monthly intervals, (e) a very large
proportion of patients are being monitored outside the
recommended intervals and (f) a significant minority
with toxic levels are not being monitored adequately.
These observations support the need for a review of the
recommendations regarding the therapeutic window for
lithium and indicate that more needs to be done to im-
prove adherence to the associated guidance on long-
term monitoring of lithium levels.
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